Premium
Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism
Author(s) -
Krishnan Venkatesh,
Ma Yanfei L,
Chen Catherine Z,
Thorne Natasha,
Bullock Heather,
Tawa Gregory,
JavellaCauley Christy,
Chu Shaoyou,
Li Weiming,
Kohn Wayne,
Adrian Mary D,
Benson Charles,
Liu Lifei,
Sato Masahiko,
Zheng Wei,
Pilon Andre M,
Yang N. Nora,
Bryant Henry U
Publication year - 2018
Publication title -
british journal of pharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.14028
Subject(s) - hypoparathyroidism , parathyroid hormone , osteoporosis , medicine , endocrinology , calcium , teriparatide , vitamin d and neurology
Human parathyroid hormone (PTH) is critical for maintaining physiological calcium homeostasis and plays an important role in the formation and maintenance of the bone. Full-length PTH and a truncated peptide form are approved for treatment of hypoparathyroidism and osteoporosis respectively. Our initial goal was to develop an improved PTH therapy for osteoporosis, but clinical development was halted. The novel compound was then repurposed as an improved therapy for hypoparathyroidism.